6 results about "Partial thromboplastin time" patented technology

A reagent for measuring activated partial thromboplastin time, the reagent comprising phosphatidylcholine (PC), phosphatidylserine (PS), and phosphatidylethanolamine (PE), wherein the ratio (PS / PC) of the concentration of the PS to the concentration of the PC is 0.26-2.00, and the concentration of the PS is 14-60 µg / mL.

The invention belongs to the technical field of polypeptide preparation and biological pharmacy, and particularly relates to eggshell membrane polypeptide with thrombin inhibition activity and application of the eggshell membrane polypeptide. According to the invention, two polypeptides are separated and purified from an eggshell membrane, and the two polypeptides are a nonapeptide YDGQHGRVS and an octapeptide EVPPSAL respectively. Tests prove that the nonapeptide YDGQHGRVS and the octapeptide EVPPSAL have thrombin inhibition activity equivalent to that of positive control heparin sodium, and discover that the nonapeptide YDGQHGRVS prolongs the activated partial thromboplastin time and the prothrombin time. The nonapeptide YDGQHGRVS and the octapeptide EVPPSAL provided by the invention are derived from eggshell membranes, are natural in source, good in thrombin inhibition activity and high in safety, and have a good application prospect.

The present invention relates to sample analysis cartridges comprising micro-environment sensors and methods for assaying coagulation in a fluid sample applied to the micro-environment sensors, and in particular, to performing coagulation assays using micro-environment sensors in a point of care sample analysis cartridge. For example, the present invention may be directed to a sample analysis cartridge including an inlet chamber configured to receive a biological sample, and a conduit fluidically connected to the inlet chamber and configured to receive the biological sample from the inlet chamber. The conduit may include a micro-environment prothrombin time (PT) sensor, and a micro-environment activated partial thromboplastin time (aPTT) sensor.

The present application belongs to the technical field of polypeptide preparation and biopharmacy, and particularly relates to eggshell membrane polypeptides with thrombin inhibitory activity and application thereof. Two polypeptides are obtained by separation and purification from eggshell membranes, which are nonapeptide YDGQHGRVS and octapeptide EVPPSPAL. It is proved by experiments that the nonapeptide YDGQHGRVS and the octapeptide EVPPSPAL have thrombin inhibitory activity equivalent to that of the positive control heparin sodium, and it is found that the nonapeptide YDGQHGRVS prolongs activated partial thromboplastin time and prothrombin time. The nonapeptide YDGQHGRVS and the octapeptide EVPPSPAL provided by the present application are derived from eggshell membranes, are natural in origin, have good thrombin inhibitory activity, high safety, and have good application prospect.

The application discloses an enhanced anti-coagulation and anti-bacterial hemodialysis hollow fiber membrane and a preparation method thereof, and belongs to the technical field of medical membrane materials. The acid activation-polydopamine coating-sulfonated grafting modification of halloysite nanotubes is carried out in the application, so that the surface sulfonic acid group density of the halloysite nanotubes reaches 0.8-2.1 mmol / g, and the Zeta potential is less than or equal to-30 mV. The modified halloysite is dispersed in a polar aprotic solvent in advance, is incorporated into a polymer matrix after ultrasonic treatment, is filtered through a sintering filter element with a diameter of less than or equal to 5 mu m, is defoamed, is spun by using a dry spraying-wet spinning method, and is prepared into a finished product through coagulation, rinsing and drying. The application constructs a heparin-like negative charge layer, so that the activated partial thromboplastin time (APTT) is greater than or equal to 55 s, platelet adhesion and protein adsorption are significantly inhibited, and the application has a broad-spectrum antibacterial performance. The rigid halloysite induces the formation of through channels, so that the pain point that a high-flux membrane is easy to damage red blood cells is solved, the process is stable, and the application is suitable for industrial production.

The invention discloses an anticoagulant peptide derived from deep sea shellfish and an application of the anticoagulant peptide in antithrombosis. Through separation, purification and structural identification, three anticoagulant polypeptides are obtained from pepsase zymolyte of deep-sea Gigandas plasmos, and the amino acid sequences of the three anticoagulant polypeptides are respectively TVTRLSD, VSQPRSTL and VVTRVVR. The anticoagulant polypeptides have the advantages that the anticoagulant polypeptides are prepared from the pepsase zymolyte of the deep-sea Gigandas plasmos, and the anticoagulant polypeptides are prepared from the pepsase zymolyte of the deep-sea Gigandas plasmos; the method comprises the following steps: obtaining polypeptide KDETRTPEEL from protease K zymolyte of deep-sea metaphila palustris; the polypeptide YLERW is obtained from the protease K zymolyte of the deep sea hippocampus (Gigantidas hamaensis), and the polypeptide YLERW is obtained from the protease K zymolyte of the deep sea hippocampus (Gigantidas hamaensis). An in-vitro anticoagulation experiment result shows that the five deep sea polypeptides can remarkably prolong activated partial thromboplastin time (APTT) and show a remarkable anticoagulation effect. Wherein the inhibition activity on the blood coagulation factor Xa and thrombin is not obvious, and good selective inhibition characteristics are shown. The novel anticoagulant peptide with blood coagulation factor XIa selective inhibitory activity is separated and identified from deep sea shellfish resources, and a novel material basis and a technical approach are provided for prevention and treatment of thrombotic diseases and development of novel biological anticoagulant preparations.